Millipore Sigma Vibrant Logo

343290 Fluoxetine, Hydrochloride - CAS 56296-78-7 - Calbiochem

Descripción

Replacement Information

Tabla espec. clave

CAS #Empirical Formula
56296-78-7C₁₇H₁₈F₃NO • HCL

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
343290-25MG
Comprobando disponibilidad...
Disponibilidad a confirmar
Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      Ampolla de plást. 25 mg
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      Solicitar precio
      Description
      OverviewA cell-permeable phenylpropylamine derived anti-depressant that acts as a selective serotonin re-uptake inhibitor (SSRI). Reported to modulate the proliferation of T-cells by increasing the Ca2+ influx and thereby influencing the activities of protein kinase A (PKA) and protein kinase C (PKC). Also shown to regulate the phosphorylation of DARPP-32 (dopamine-and cAMP-regulated phosphoprotein of Mr 32,000) and AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors. Shown to trigger oxidative stress-induced apoptotic cell death. Also reported to initiate signaling pathways in neuronal cells leading to activation of ERK and NF-κB.
      Catalogue Number343290
      Brand Family Calbiochem®
      Synonymsdl-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine, HCl, (±)-N-Methyl-3-phenyl-3-[(α,α,α-trifluoro-p-tolyl)oxy]propylamine, HCl, LY-110140, Prozac
      References
      ReferencesBartholoma, P., et al. 2002. Biochem. Pharmacol. 63, 1507.
      Bian, J.T., et al. 2002. Eur. J. Pharmacol. 453, 159.
      Zhang, A., et al. 2002. J. Med. Chem. 45, 1930.
      Svenningsson, P., et al. 2002. Proc. Natl. Acad. Sci. USA 99, 3182.
      Edgar, V.A., et al. 1999. Eur. J. Pharmacol. 372, 65.
      Product Information
      CAS number56296-78-7
      ATP CompetitiveN
      FormSolid
      Hill FormulaC₁₇H₁₈F₃NO • HCL
      Chemical formulaC₁₇H₁₈F₃NO • HCL
      Hygroscopic Hygroscopic
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetSelective serotonin re-uptake inhibitor
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Harmful
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      343290-25MG 04055977195101

      Documentation

      Fluoxetine, Hydrochloride - CAS 56296-78-7 - Calbiochem Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      Fluoxetine, Hydrochloride - CAS 56296-78-7 - Calbiochem Certificados de análisis

      CargoNúmero de lote
      343290

      Referencias bibliográficas

      Visión general referencias
      Bartholoma, P., et al. 2002. Biochem. Pharmacol. 63, 1507.
      Bian, J.T., et al. 2002. Eur. J. Pharmacol. 453, 159.
      Zhang, A., et al. 2002. J. Med. Chem. 45, 1930.
      Svenningsson, P., et al. 2002. Proc. Natl. Acad. Sci. USA 99, 3182.
      Edgar, V.A., et al. 1999. Eur. J. Pharmacol. 372, 65.
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision05-July-2017 JSW
      Synonymsdl-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine, HCl, (±)-N-Methyl-3-phenyl-3-[(α,α,α-trifluoro-p-tolyl)oxy]propylamine, HCl, LY-110140, Prozac
      DescriptionA cell-permeable phenylpropylamine derived anti-depressant that acts as a selective serotonin re-uptake inhibitor (SSRI). Reported to modulate the proliferation of T cells by increasing the Ca2+ influx thereby influencing the activities of protein kinase A (PKA) and protein kinase C (PKC). Inhibits leak K+ currents in a reversible and voltage-independent manner (IC50 = 780 nM). Also shown to regulate the phosphorylation of DARPP-32 (dopamine-and cAMP-regulated phosphoprotein of Mr 32,000) and AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors. Triggers oxidative stress-induced apoptotic cell death and initiates signaling pathways in neuronal cells leading to an activation of ERK and NF-κB.
      FormSolid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number56296-78-7
      Chemical formulaC₁₇H₁₈F₃NO • HCL
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityH₂O (5 mg/ml) or Methanol (100 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Harmful
      Merck USA index14, 4185
      ReferencesBartholoma, P., et al. 2002. Biochem. Pharmacol. 63, 1507.
      Bian, J.T., et al. 2002. Eur. J. Pharmacol. 453, 159.
      Zhang, A., et al. 2002. J. Med. Chem. 45, 1930.
      Svenningsson, P., et al. 2002. Proc. Natl. Acad. Sci. USA 99, 3182.
      Edgar, V.A., et al. 1999. Eur. J. Pharmacol. 372, 65.